Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Marwan, Bachour"'
Autor:
Grigoris T, Gerotziafas, Ali, Taher, Hikmat, Abdel-Razeq, Essam, AboElnazar, Alex C, Spyropoulos, Salem, El Shemmari, Annette K, Larsen, Ismail, Elalamy, Marwan, Bachour
Publikováno v:
The Oncologist
The COMPASS‐CAT study was undertaken in outpatients with breast, colon, lung, or ovarian cancer. The aim of the study was to identify the most relevat risk factors for symptomatic thromboembolism and to develop a risk assessment model applicable to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b72672b438a9349993afefb3aff2e578
https://doi.org/10.1634/theoncologist.2016-0414
https://doi.org/10.1634/theoncologist.2016-0414
Publikováno v:
Investigational New Drugs. 34:474-480
Background Treatment options for patients with metastatic castration-resistance prostate cancer are unsatisfactory. Docetaxel monotherapy offers promising results with a tolerable toxicity profile. However, enhancing the clinical index of Docetaxel-b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e8b398f9a795c4a8a16ce25d9da776e
https://doi.org/10.1007/s10637-016-0357-4
https://doi.org/10.1007/s10637-016-0357-4
Metastatic castration resistant prostate cancer: current strategies of management in the Middle East
Autor:
Marwan Bachour, Naim Farah, Shouki Bazarbashi, Ali Shamseddine, Mohamed Jaloudi, Tahseen Alrubai, Deborah Mukherji, Hassan Jaafar, Muhammad Bulbul, Mohammed F Alotaibi
Publikováno v:
Critical reviews in oncology/hematology. 90(1)
Although most patients with prostate cancer respond to initial androgen-deprivation therapy, progression to castration-resistant prostate cancer (CRPC) is almost inevitable. In 2004, the docetaxel/prednisone regimen was approved for the management of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68aee6bfafacf161cde89babec4288d9
https://pubmed.ncbi.nlm.nih.gov/24289901
https://pubmed.ncbi.nlm.nih.gov/24289901